Cerenome (PSTV) Debt Ratio (2010 - 2026)

Plus Therapeutics (PSTV) posted quarterly Debt Ratio of 0.03 for Q1 2026, down 27.1% quarter-over-quarter from 0.05 in Q4 2025.

Cerenome (PSTV) Debt Ratio (2010 - 2026) Analysis & Trends

Plus Therapeutics (PSTV) has reported Debt Ratio for 17 consecutive years, with 0.03 the latest figure, recorded in Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.03; the TTM figure through Mar 2026 stood at 0.03 (changed N/A YoY), while the FY2025 annual figure was 0.05, down 90.74% from the prior year.
Debt Ratio retreated to 0.03 in Q1 2026 per PSTV's latest filing, from 0.05 in the prior quarter.
Across five years, Debt Ratio topped out at 0.64 in Q1 2024 and bottomed at 0.03 in Q1 2026.
Historically, Debt Ratio has averaged 0.31 across 5 years, with a median of 0.31 in 2023.
Annual changes were most pronounced in 2024 — Debt Ratio soared 97.5% — and 2025, when it plunged 90.74%.
Plus Therapeutics' Debt Ratio stood at 0.23 in 2022, then soared by 54.48% to 0.35 in 2023, then jumped by 42.15% to 0.5 in 2024, then slumped by 90.74% to 0.05 in 2025, then decreased by 27.1% to 0.03 in 2026.
Business Quant data shows PSTV's Debt Ratio at 0.03 in Q1 2026, 0.05 in Q4 2025, and 0.5 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Cerenome	28.07 Mn	19.48 Mn	-	-

Download Data